Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

186
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
186
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

426
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
426
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

147
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
147
Drug Nomenclature01:17

Drug Nomenclature

2.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
2.8K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.1K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.1K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-Time Benefit Tools in 2026-More Work Is Needed.

JAMA network open·2026
Same author

Antihypertensive Medication Use and Prescription Discontinuation Among Postpartum Women.

American journal of hypertension·2026
Same author

Trajectories of Treatment Disruption for Chronic Outpatient Medications for U.S. Veterans During Drug Shortages.

Pharmacoepidemiology and drug safety·2026
Same author

Age-Related Patterns and Longitudinal Trends in Psychotropic Medication Use Among Commercially Insured Children with Autism Spectrum Disorder in the United States: A Claims Database Study.

Journal of child and adolescent psychopharmacology·2026
Same author

Medication use for patients with obesity: trends and characteristics for US employees.

The American journal of managed care·2026
Same author

Drug supply chain disruptions and outpatient medication shortages in the Veterans Health Administration, 2017-2020.

Exploratory research in clinical and social pharmacy·2026
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development, use and psychometric properties of vision and hearing bolt-ons for EQ-5D-3L and EQ-5D-5L: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles

Related Experiment Video

Updated: Dec 27, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

520

Value-Based Pharmaceutical Contracts: Value for Whom?

Joseph T Kannarkat1, Chester B Good2, Natasha Parekh3

  • 1Department of Politics and International Studies, University of Cambridge, Cambridge, England, UK.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|March 2, 2020
PubMed
Summary
This summary is machine-generated.

Value-based pharmaceutical contracts (VBPCs) link drug reimbursement to patient outcomes. To effectively reduce costs, VBPCs require a patient-centered approach and integration into broader payer strategies.

Keywords:
drug pricingpharmaceutical contractsvalue-based contracts

More Related Videos

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

2.1K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K

Related Experiment Videos

Last Updated: Dec 27, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

520
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

2.1K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Healthcare Management

Background:

  • Value-based pharmaceutical contracts (VBPCs) are agreements linking drug reimbursement to patient outcomes.
  • These contracts are complex, with unclear benefits for stakeholders.
  • VBPCs differ from payer-provider arrangements in incentive alignment and performance metrics.

Discussion:

  • Examining the impact of VBPCs on medication costs, clinical results, and patient access.
  • Comparing VBPCs with value-based payer-provider arrangements regarding reimbursement and incentives.
  • Analyzing the complexities and stakeholder benefits within VBPCs.

Key Insights:

  • VBPCs alone are unlikely to significantly reduce overall healthcare costs.
  • A patient-centered strategy is crucial for effective VBPC implementation.
  • Integrating VBPCs into comprehensive payer drug cost reduction plans is recommended.

Outlook:

  • Future VBPC models should prioritize patient outcomes and equitable access.
  • Further research is needed to optimize VBPC structures for cost-effectiveness.
  • Policy development should focus on aligning VBPC incentives with broader healthcare goals.